Fall 9-1-2000

PHAR 552.01: Therapeutics III

Michael P. Rivey  
*University of Montana - Missoula*, michael.rivey@umontana.edu

Douglas Allington  
*University of Montana - Missoula*, douglas.allington@umontana.edu

Donna G. Beall  
*University of Montana - Missoula*, donna.beall@umontana.edu

Follow this and additional works at: [https://scholarworks.umt.edu/syllabi](https://scholarworks.umt.edu/syllabi)

**Let us know how access to this document benefits you.**

**Recommended Citation**

Rivey, Michael P.; Allington, Douglas; and Beall, Donna G., "PHAR 552.01: Therapeutics III" (2000). *Syllabi*. 5281.  
[https://scholarworks.umt.edu/syllabi/5281](https://scholarworks.umt.edu/syllabi/5281)

This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.
Pharmacy 552 & 595 B.S. : Therapeutics III (+) Fall 2000

Lectures: M-W-Th-F 0910-1000 Rm 111, Skaggs Building
(note: Fri-Mon joint lectures with Pharm.D class in SB114)
(note: 595 lectures on Thurs 1010-1100 in SB 336)

Course Coordinator: Michael Rivey M. Rivey
Instructors: Douglas Allington Office: 243-6796
            Rose Macklin Community Hosp: 728-4100
            Cathy Bartels ext. 7605
            Sarah Miller Pager: 329-6122
            Gayle Cochran Home: 251-3369
            Donna Beall Larry Dent
            Lee Ann Bradley Vince Colucci
            William Docktor

Material and Resources
Required Texts: DiPiro *Pharmacotherapy, 4th edition*
Pray *Nonprescription Product Therapeutics* or APhA: *Handbook of Nonprescription Drugs*
Medical Letter on Drugs & Therapeutics
Goodman & Gilman's *Pharmacological Basis of Therapeutics*
Boh *Clinical Clerkship Manual*
A medical dictionary

Optional Texts: Murphy: *Clinical Pharmacokinetics pocket reference*
Evans: *Applied Pharmacokinetics*
Young, Koda-Kimble: *Applied Therapeutics*
Herfindal, Gourley, Hart: *Clinical Pharmacy and Therapeutics*
Hansten & Horn: *Drug Interactions*
Pagana & Pagana: *Diagnostic & Lab Test Ref.*, or other lab. text

Goals of the Course

To promote the students' understanding of common disease states with particular emphasis on the facets of diseases that are amenable to drug therapy.

To familiarize the student with the proper use of drugs in a clinical setting.

To develop the students' awareness of factors that should be considered prior to selection of a drug and the appropriate parameters that should be monitored for therapeutic as well as undesired effects.

To encourage the students' ability to problem-solve in the clinical setting.
GRADING IN COURSE: Phar 552-BS Therapeutics

3 midterm exams: 100 points each  
Final exam (comprehensive, multiple choice)  
(100 pts comprehensive, 30 pts over last 6 lectures)  

Topic quizzes: 8 quizzes graded on 10 pts each  

TOTAL POINTS FOR COURSE  

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic and encourage class attendance and attention. Quizzes will occur after topic lectures and will test understanding of basic concepts in the reading assignments as well as issues discussed or emphasized in lecture. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. Quiz on syllabus indicates a quiz will be given for the overall topic at end of the given lecture. Lowest 2 quiz grades will be thrown out; no make-ups will be allowed for quiz. Scoring: Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & Pray books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, with instructor permission. The “make-up” requirement for a conference will be at the discretion of the instructor, dependent on the topic.

Exams:
3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a “common” time period of 8-10AM on select Thursdays. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your student colleagues have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They do not appreciate any “side” conversations while the instructor is lecturing. They do appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of “what” constitutes disruption. Please note that we encourage questions and relevant discussion.
Performance Objectives
Upon completion of this course, each student shall be able to:

Relate the pathophysiology of a disease to the known or purported action of a drug.

Evaluate the seriousness of a disorder based on the signs and symptoms related to a diagnosed problem, and:
- determine the necessity of drug therapy,
- when applicable, choose the proper drug and/or drug product for the situation.

Determine the place of non-pharmacologic and natural therapies, when applicable.

Tailor the drug therapy of an individual based on patient characteristics and known pharmacokinetics principles.

Identify potential drug-drug interactions.

Monitor the appropriate parameters of a disease to determine if the patient is responding positively to therapy.

Monitor for adverse drug reactions and exacerbations of underlying patient problems resulting from drug therapy.

Student Responsibilities and Obligations

* To attend and participate in lecture sessions.

* To do assigned readings from the texts.

* To attend Integrated Studies conferences, prepare each case in advance, prepare to present a patient case, and participate in the discussion of all patient presentations.

* To perform satisfactorily on course quizzes and lecture examinations.
GRADING IN COURSE: Phar 552-BS Therapeutics

3 midterm exams: 100 points each
Final exam (comprehensive, multiple choice)
(100 pts comprehensive, 30 pts over last 6 lectures) 300 points

Topic quizzes: 8 quizzes graded on 10 pts each

TOTAL POINTS FOR COURSE 430 POINTS

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic and encourage class attendance and attention. Quizzes will occur after topic lectures and will test understanding of basic concepts in the reading assignments as well as issues discussed or emphasized in lecture. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. Quiz on syllabus indicates a quiz will be given for the overall topic at end of the given lecture. Lowest 2 quiz grades will be thrown out; no make-ups will be allowed for quiz. Scoring: Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & Pray books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, with instructor permission. The “make-up” requirement for a conference will be at the discretion of the instructor, dependent on the topic.

Exams:
3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a “common” time period of 8-10AM on select Thursdays. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your student colleagues have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They do not appreciate any “side” conversations while the instructor is lecturing. They do appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of “what” constitutes disruption. Please note that we encourage questions and relevant discussion.
Therapeutics III 552 B.S. & Phar 595 supplemental course; Lecture Syllabus

<table>
<thead>
<tr>
<th>Instructor</th>
<th>Reading (DiPiro, Pray)</th>
</tr>
</thead>
</table>

Sept
6W Introduction/ Liver disease  MPR
7Th Liver disease  MPR
7Th Liver disease (10AM in SB 114)  MPR (595)
8F Renal disease (10AM in SB 114)  DRA

11M Renal disease/ quiz  DRA
13W Hypertension  LAD
14Th HTN  LAD
14Th HTN  LAD (595)
15F Pain Management (10 AM SB114)  LAB  56, OTC 18

18M Pain mgmt (10AM SB114)/ quiz  LAB
20W Hyperlipidemia  LAD
21Th Hyperlipidemia  LAD
21Th Drug Literature Evaluation  CLB (595)
22F Headache (10AM SB 114)  DB  57

25M Headache (10AM SB 114)  DB  OTC 18
27W Congestive Heart Failure  VJC  11
28Th CHF/ quiz (10-11AM)  VJC
28Th Drug Literature Evaluation (9-10AM)  CLB (595)
29F Digoxin kinetics  VJC

Oct
2M Dig. PK  VJC
4W OFF DAY; CAREER FAIR
5Th Test 1 at 8-10AM in SB 114; through Digoxin PK
5Th Drug Literature Evaluation  CLB (595)
6F Coronary artery disease  VJC  12

9M CAD  VJC
11W Dysrhythmias  VJC  14
12Th Arthritis  MPR  83,84
12Th Arthritis  MPR (595)
13F Arthritis/ quiz  MPR  OTC 18,20

16M Contraception  DB  OTC 43
18W Contraception/ quiz  DB  76
19Th Diabetes mellitis  LRM  70
19Th Contraception/ quiz  DB (595)
20F DM  LRM
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct 23</td>
<td>DM/ quiz</td>
<td>LRM OTC 46</td>
</tr>
<tr>
<td>25W</td>
<td>Menopause</td>
<td>GAC 78</td>
</tr>
<tr>
<td>26Th</td>
<td>Menopause</td>
<td>GAC</td>
</tr>
<tr>
<td>26Th</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
</tr>
<tr>
<td>27F</td>
<td>Osteoporosis (10AM in SB 114)</td>
<td>GAC 82, OTC pp.711,713</td>
</tr>
<tr>
<td>30M</td>
<td>Osteoporosis (10AM in SB 114)</td>
<td>GAC 61</td>
</tr>
<tr>
<td>Nov 1W</td>
<td>Dementia</td>
<td>GAC</td>
</tr>
<tr>
<td>2Th</td>
<td>Test 2 at 8-10AM in SB 114; through osteoporosis</td>
<td>CLB (595)</td>
</tr>
<tr>
<td>2Th</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
</tr>
<tr>
<td>3F</td>
<td>Fluid &amp; electrolytes</td>
<td>SJM DiPiro pp. 890-901</td>
</tr>
<tr>
<td>6M</td>
<td>Fluid &amp; electrolytes</td>
<td>SJM pp. 902-16</td>
</tr>
<tr>
<td>8W</td>
<td>Nutrition</td>
<td>SJM</td>
</tr>
<tr>
<td>9Th</td>
<td>Oncology overview</td>
<td>CLB DiPiro pp.2013-41</td>
</tr>
<tr>
<td>9Th</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
</tr>
<tr>
<td>10F</td>
<td>VETERANS DAY HOLIDAY</td>
<td></td>
</tr>
<tr>
<td>13M</td>
<td>Oncology</td>
<td>CLB</td>
</tr>
<tr>
<td>15W</td>
<td>Nausea &amp; vomiting</td>
<td>LAB 33, OTC 5</td>
</tr>
<tr>
<td>16Th</td>
<td>Seizure disorders</td>
<td>DRA 52</td>
</tr>
<tr>
<td>16Th</td>
<td>Seizure dx/ quiz</td>
<td>DRA (595)</td>
</tr>
<tr>
<td>17F</td>
<td>Anticonvulsant kinetics</td>
<td>DRA</td>
</tr>
<tr>
<td>20M</td>
<td>Thromboembolic dx (10AM in SB114)</td>
<td>MPR 17</td>
</tr>
<tr>
<td>22W</td>
<td>OFF; TRAVEL DAY</td>
<td></td>
</tr>
<tr>
<td>23Th</td>
<td>THANKSGIVING HOLIDAY</td>
<td></td>
</tr>
<tr>
<td>24F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27M</td>
<td>TED (10AM in SB 114)/ quiz</td>
<td>MPR 18</td>
</tr>
<tr>
<td>29W</td>
<td>Stroke</td>
<td>MPR 71</td>
</tr>
<tr>
<td>30Th</td>
<td>Thyroid disorders</td>
<td>MPR</td>
</tr>
<tr>
<td>30Th</td>
<td>Biostatistics overview</td>
<td>TPS (595)</td>
</tr>
<tr>
<td>Dec 1F</td>
<td>Obstructive Airways Disease (10AM in SB 114)</td>
<td>DRA 24, OTC 17</td>
</tr>
<tr>
<td>4M</td>
<td>OAD (10 AM in SB 114) / quiz</td>
<td>DRA 25</td>
</tr>
<tr>
<td>6W</td>
<td>Theophylline kinetics</td>
<td>DRA</td>
</tr>
<tr>
<td>7Th</td>
<td>test 3 at 8-10AM in SB 114; through OAD</td>
<td></td>
</tr>
<tr>
<td>7Th</td>
<td>Biostatistics overview</td>
<td>TPS (595)</td>
</tr>
<tr>
<td>8F</td>
<td>Anxiety/sleep disorders</td>
<td>WJD 67,69, OTC 24</td>
</tr>
</tbody>
</table>
Pharmacy 595: supplemental course

Phar 595: Course is 1-hour Thursday session to supplement Ther-III and cover other topics not in B.S. curriculum in an overview fashion. It is graded course

Schedule: merged to above syllabus (weekly on Thurs at 1010-1100 in SB 336)

Instructors: various Therapeutics instructors

Cathy Bartels
Tim Stratton

Grading in Phar 595:

6/14 of course grade: project in Drug Literature Evaluation
3/14 of course grade: biostatistics questions on Final Exam (add-on questions)
5/14 of course grade: grade obtained in Ther. Phar 552 course
Integrated Studies Phar 574

I. Conference topics

Group 1: SB 337 Tues 0910-1100 Colucci
Group 2: SB 215 " " Rivey

week of:

September 4M no conference
11M Liver disease case
18M Hypertension case
25M Headache/pain management

October 2M Digoxin kinetics
9M service learning update: J-club for ½ of class
16M OTC cases
23M Contraception
30M Diabetes

November 6M service learning update: J-club for other ½ of class
13M SEMINARS
20M off week- holiday week
27M TED case

December 4M OAD case
11M OTC cases

Seminar: A required activity in the course, graded on a pass/no-pass basis. Student must repeat a no-pass seminar to successfully pass course.